NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells

NEW YORK, March 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. AMEX: NBS, which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that Robin Smith, MD, MBA, and NeoStem's Chairman and Chief Executive Officer was featured in a WCBS-TV Health Watch segment on adult stem cells.

The Health Watch segment discussed the tremendous promise of adult stem cells as therapies for a variety of diseases and highlighted several early clinical successes in certain auto-immune and cardiac disorders. Dr. Smith shared NeoStem's role in the adult stem cell market through the Company's safe, and non-invasive method of collecting and storing adult stem cells from healthy individuals for their own use in the future.

    The segment may be viewed online at:
http://wcbstv.com/video/?id=110029@wcbs.dayport.com.

About NeoStem, Inc.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission.

    Contact:

    NeoStem, Inc.
    Robin Smith, Chief Executive Officer
    T: 212-584-4180
    E: rsmith@neostem.com
    www.neostem.com